Eli Lilly, Regeneron COVID treatments de-authorized by FDA as ineffective vs. omicron
The FDA said the two treatments are unlikely to work against the omicron variant, which makes up 99% of U.S. cases.
Real Unbias Media For Real In The Know People!
The FDA said the two treatments are unlikely to work against the omicron variant, which makes up 99% of U.S. cases.